Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
Commentary|Videos|June 16, 2025

Leveraging Technology to Enhance Cancer Clinical Trial Recruitment

In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer Network (NCCN), explores how emerging technologies such as wearable devices, real-world data analysis, and decentralized trial designs can improve the identification and engagement of potential cancer clinical trial participants.

In a recent video interview with Applied Clinical Trials, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer Network (NCCN), discussed the current state and challenges of cancer patient participation in clinical trials. Barriers to participation can include lack of understanding, economic burdens, and implicit biases. Robinson highlighted solutions such as increased education, legislation like the Clinical Trials Modernization Act, and engaging patients early in trial design. He also touched on the use of technology, such as biomarker testing and wearable devices, which can also enhance recruitment and reduce burdens.

ACT: In what ways can technology be utilized to identify and engage potential cancer trial participants more effectively?

Robinson: This is actually a really exciting topic to me, because I think we are in an era where we can truly engage technology to help answer these kinds of questions. As I mentioned earlier, trials are becoming more and more complex because of the targeted therapies that we're testing in them, so using the kinds of modalities and technology that is available now for biomarker testing, real-world evidence, so large dataset analysis to really understand what patients have an opportunity to respond to these targeted therapies, etc. and you can sort of hone in on them, on those patients for trying to recruit them, is important. I think technology can also be used to address these economic and time burdens as well. When you think about smart watches, cell phone apps, wearable devices, a lot of the time and economic burden comes from patients having to travel back for extra scans, extra lab tests, those sorts of things. You can envision ways in which that technology can be used to supplement or take the place of those tests. Similarly, you can use in home testing to reduce travel time, to decentralize the trial designs. I think you could even take advantage of technology for developing better educational materials as well, so lots of opportunity, and I think it's an area of active research.


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.